Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome

Wendy Y. Craig, James E. Haddow, Glenn E. Palomaki, Richard I. Kelley, Lisa Kratz, Cedric H L Shackleton, Josep Marcos, G. Stephen Tint, Andrew R. MacRae, Malgorzata J. Nowaczyk, Edward M. Kloza, Mira B. Irons, Marie Roberson

Research output: Contribution to journalArticle

Abstract

Background: Smith-Lemli-Opitz syndrome (SLOS) is a rare hereditary disorder of cholesterol metabolism. We examine the feasibility of identifying SLOS as a part of a routine prenatal screening and evaluate diagnostic testing in maternal urine (or serum), in addition to amniotic fluid. Methods: Our SLOS risk algorithm utilized three Down syndrome screening markers (estimated 62% detection rate; 0.3% screen-positive rate). Fifteen North American prenatal screening programs implemented this algorithm. Results: SLOS risk was assigned to 1 079 301 pregnancies; 3083 were screen-positive (0.29%). Explanations were found for 1174, including 914 existing fetal deaths. Among the remaining pregnancies, 739 were screen-positive only for SLOS; 1170 were also screen-positive for other fetal disorders. Five of six SLOS pregnancies (83%) were screen-positive. All six had sonographic findings, were biochemically confirmed, and were terminated. Maternal urine steroid measurements were confirmatory in four cases tested. Second-trimester prevalence among Caucasians was 1 in 101 000 (1 in 130000 overall; no cases in other racial groups). Among 739 pregnancies screen-positive only for SLOS. two cases were identified; another 69 had major fetal abnormalities. Conclusions: Although SLOS occurred less often than previously reported, many other major abnormalities were detected. Implementing the algorithm as an adjunct to Down syndrome screening may be feasible.

Original languageEnglish (US)
Pages (from-to)842-849
Number of pages8
JournalPrenatal Diagnosis
Volume26
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Smith-Lemli-Opitz Syndrome
Down Syndrome
Prenatal Diagnosis
Pregnancy
Mothers
Urine
Fetal Death
Second Pregnancy Trimester
Amniotic Fluid
Steroids
Cholesterol

Keywords

  • Diagnostic testing
  • Prenatal screening
  • Prevalence
  • Smith-Lemli-Opitz syndrome

ASJC Scopus subject areas

  • Genetics(clinical)
  • Obstetrics and Gynecology

Cite this

Craig, W. Y., Haddow, J. E., Palomaki, G. E., Kelley, R. I., Kratz, L., Shackleton, C. H. L., ... Roberson, M. (2006). Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. Prenatal Diagnosis, 26(9), 842-849. https://doi.org/10.1002/pd.1518

Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. / Craig, Wendy Y.; Haddow, James E.; Palomaki, Glenn E.; Kelley, Richard I.; Kratz, Lisa; Shackleton, Cedric H L; Marcos, Josep; Stephen Tint, G.; MacRae, Andrew R.; Nowaczyk, Malgorzata J.; Kloza, Edward M.; Irons, Mira B.; Roberson, Marie.

In: Prenatal Diagnosis, Vol. 26, No. 9, 09.2006, p. 842-849.

Research output: Contribution to journalArticle

Craig, WY, Haddow, JE, Palomaki, GE, Kelley, RI, Kratz, L, Shackleton, CHL, Marcos, J, Stephen Tint, G, MacRae, AR, Nowaczyk, MJ, Kloza, EM, Irons, MB & Roberson, M 2006, 'Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome', Prenatal Diagnosis, vol. 26, no. 9, pp. 842-849. https://doi.org/10.1002/pd.1518
Craig, Wendy Y. ; Haddow, James E. ; Palomaki, Glenn E. ; Kelley, Richard I. ; Kratz, Lisa ; Shackleton, Cedric H L ; Marcos, Josep ; Stephen Tint, G. ; MacRae, Andrew R. ; Nowaczyk, Malgorzata J. ; Kloza, Edward M. ; Irons, Mira B. ; Roberson, Marie. / Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome. In: Prenatal Diagnosis. 2006 ; Vol. 26, No. 9. pp. 842-849.
@article{b5c2d49ac009436f8ac1fca0a2c41a28,
title = "Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome",
abstract = "Background: Smith-Lemli-Opitz syndrome (SLOS) is a rare hereditary disorder of cholesterol metabolism. We examine the feasibility of identifying SLOS as a part of a routine prenatal screening and evaluate diagnostic testing in maternal urine (or serum), in addition to amniotic fluid. Methods: Our SLOS risk algorithm utilized three Down syndrome screening markers (estimated 62{\%} detection rate; 0.3{\%} screen-positive rate). Fifteen North American prenatal screening programs implemented this algorithm. Results: SLOS risk was assigned to 1 079 301 pregnancies; 3083 were screen-positive (0.29{\%}). Explanations were found for 1174, including 914 existing fetal deaths. Among the remaining pregnancies, 739 were screen-positive only for SLOS; 1170 were also screen-positive for other fetal disorders. Five of six SLOS pregnancies (83{\%}) were screen-positive. All six had sonographic findings, were biochemically confirmed, and were terminated. Maternal urine steroid measurements were confirmatory in four cases tested. Second-trimester prevalence among Caucasians was 1 in 101 000 (1 in 130000 overall; no cases in other racial groups). Among 739 pregnancies screen-positive only for SLOS. two cases were identified; another 69 had major fetal abnormalities. Conclusions: Although SLOS occurred less often than previously reported, many other major abnormalities were detected. Implementing the algorithm as an adjunct to Down syndrome screening may be feasible.",
keywords = "Diagnostic testing, Prenatal screening, Prevalence, Smith-Lemli-Opitz syndrome",
author = "Craig, {Wendy Y.} and Haddow, {James E.} and Palomaki, {Glenn E.} and Kelley, {Richard I.} and Lisa Kratz and Shackleton, {Cedric H L} and Josep Marcos and {Stephen Tint}, G. and MacRae, {Andrew R.} and Nowaczyk, {Malgorzata J.} and Kloza, {Edward M.} and Irons, {Mira B.} and Marie Roberson",
year = "2006",
month = "9",
doi = "10.1002/pd.1518",
language = "English (US)",
volume = "26",
pages = "842--849",
journal = "Prenatal Diagnosis",
issn = "0197-3851",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Identifying Smith-Lemli-Opitz syndrome in conjunction with prenatal screening for Down syndrome

AU - Craig, Wendy Y.

AU - Haddow, James E.

AU - Palomaki, Glenn E.

AU - Kelley, Richard I.

AU - Kratz, Lisa

AU - Shackleton, Cedric H L

AU - Marcos, Josep

AU - Stephen Tint, G.

AU - MacRae, Andrew R.

AU - Nowaczyk, Malgorzata J.

AU - Kloza, Edward M.

AU - Irons, Mira B.

AU - Roberson, Marie

PY - 2006/9

Y1 - 2006/9

N2 - Background: Smith-Lemli-Opitz syndrome (SLOS) is a rare hereditary disorder of cholesterol metabolism. We examine the feasibility of identifying SLOS as a part of a routine prenatal screening and evaluate diagnostic testing in maternal urine (or serum), in addition to amniotic fluid. Methods: Our SLOS risk algorithm utilized three Down syndrome screening markers (estimated 62% detection rate; 0.3% screen-positive rate). Fifteen North American prenatal screening programs implemented this algorithm. Results: SLOS risk was assigned to 1 079 301 pregnancies; 3083 were screen-positive (0.29%). Explanations were found for 1174, including 914 existing fetal deaths. Among the remaining pregnancies, 739 were screen-positive only for SLOS; 1170 were also screen-positive for other fetal disorders. Five of six SLOS pregnancies (83%) were screen-positive. All six had sonographic findings, were biochemically confirmed, and were terminated. Maternal urine steroid measurements were confirmatory in four cases tested. Second-trimester prevalence among Caucasians was 1 in 101 000 (1 in 130000 overall; no cases in other racial groups). Among 739 pregnancies screen-positive only for SLOS. two cases were identified; another 69 had major fetal abnormalities. Conclusions: Although SLOS occurred less often than previously reported, many other major abnormalities were detected. Implementing the algorithm as an adjunct to Down syndrome screening may be feasible.

AB - Background: Smith-Lemli-Opitz syndrome (SLOS) is a rare hereditary disorder of cholesterol metabolism. We examine the feasibility of identifying SLOS as a part of a routine prenatal screening and evaluate diagnostic testing in maternal urine (or serum), in addition to amniotic fluid. Methods: Our SLOS risk algorithm utilized three Down syndrome screening markers (estimated 62% detection rate; 0.3% screen-positive rate). Fifteen North American prenatal screening programs implemented this algorithm. Results: SLOS risk was assigned to 1 079 301 pregnancies; 3083 were screen-positive (0.29%). Explanations were found for 1174, including 914 existing fetal deaths. Among the remaining pregnancies, 739 were screen-positive only for SLOS; 1170 were also screen-positive for other fetal disorders. Five of six SLOS pregnancies (83%) were screen-positive. All six had sonographic findings, were biochemically confirmed, and were terminated. Maternal urine steroid measurements were confirmatory in four cases tested. Second-trimester prevalence among Caucasians was 1 in 101 000 (1 in 130000 overall; no cases in other racial groups). Among 739 pregnancies screen-positive only for SLOS. two cases were identified; another 69 had major fetal abnormalities. Conclusions: Although SLOS occurred less often than previously reported, many other major abnormalities were detected. Implementing the algorithm as an adjunct to Down syndrome screening may be feasible.

KW - Diagnostic testing

KW - Prenatal screening

KW - Prevalence

KW - Smith-Lemli-Opitz syndrome

UR - http://www.scopus.com/inward/record.url?scp=33749459449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749459449&partnerID=8YFLogxK

U2 - 10.1002/pd.1518

DO - 10.1002/pd.1518

M3 - Article

C2 - 16832833

AN - SCOPUS:33749459449

VL - 26

SP - 842

EP - 849

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

SN - 0197-3851

IS - 9

ER -